Press release
Rising Smoking Rates Fueling Growth in the Primary Biliary Cholangitis Market: A Significant Driver Propelling The Primary Biliary Cholangitis Market In 2025
Primary Biliary Cholangitis Market
What Is the Primary Biliary Cholangitis Market Size and Projected Growth Rate?
The market size for primary biliary cholangitis has seen a swift expansion in the last few years. It's projected to escalate from $0.98 billion in 2024 to $1.09 billion in 2025, recording a compound annual growth rate (CAGR) of 11.8%. Factors such as heightened disease awareness, surge in worldwide health care spending, strategic partnerships within the healthcare industry, emphasis on patient representation, and governmental liver health initiatives, can all be credited for the growth experienced during the historic period.
The market size for primary biliary cholangitis is projected to experience robust gains in the near future, swaying to an expected $1.6 billion by 2029, with an annual average growth rate (CAGR) of 9.9%. This forecasted surge is a result of factors including the expansion in biomarker research, worldwide initiatives in managing rare diseases, heightened collaborations in clinical trials, and a holistic approach to patient healthcare, along with the escalating need for liver transplants. Key shifts that are expected during the forecast period expand to advancements in biomarker research, a growing emphasis on non-harmful diagnostic methods, study concentration on immune-modifying treatments. Integration of artificial intelligence (AI), patient feedback outcomes incorporated in clinical trials, telemedicine for patient care, the concentration on combination therapies, and emerging treatments targeting fibrosis are also expected growth-drivers.
Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13520
What Are the Major Segments in the Primary Biliary Cholangitis Market?
The primary biliary cholangitis market covered in this report is segmented -
1) By Treatment Type: Drugs, Liver Transplantation
2) By Diagnosis: Imaging Tests, Magnetic Resonance Elastography (MRE), Magnetic Resonance Cholangiopancreatography (MRCP), Ultrasound, Fibroscan, Blood Tests, Cholesterol Test, Antibody Tests, Liver Tests, Other Diagnoses
3) By End-Users: Specialty Clinics, Homecare, Other End-Users
Subsegments:
1) By Drugs: Ursodeoxycholic Acid (UDCA), Obeticholic Acid (OCA), Fibrates, Immunosuppressive Drugs, Other Targeted Therapies
2) By Liver Transplantation: Orthotopic Liver Transplantation (OLT), Living Donor Liver Transplantation, Hepatobiliary Surgery For Liver Transplant
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13520&type=smp
What Are The Driving Primary Biliary Cholangitis Market Evolution?
The rise in smoking rates is anticipated to spark a surge in the primary biliary cholangitis market. The term 'smoking' refers to the act of inhaling and exhaling smoke resulting from the burning of tobacco or other items. Liver diseases, including PBC, have been connected to the habit of smoking. Increased smoking can thus lead to higher numbers of people seeking treatment for liver-related ailments. For instance, official data from Statistics Canada released in July 2023, revealed that cigarette production in Canada had seen a boost of 2.2% compared to June 2023. Furthermore, June witnessed a 2.6% augmentation in cigarette sales, peaking at 1.4 billion units relative to May. Hence, an increment in smoking is set to augment the growth of the primary biliary cholangitis market. The escalating number of liver cancer cases is also projected to stimulate the growth of the primary biliary cholangitis market. Liver cancer originates in the cells of the liver. The connection between primary biliary cholangitis and liver cancer is substantial due to the heightened risk of various malignancies, including cholangiocarcinoma and hepatocellular carcinoma. The increasing occurrence of the ailment and its possible complications also add to the growth of this market. As per the American Cancer Society's projections in January 2024, the U.S is speculated to witness about 41,630 fresh cases of liver cancer, with 28,000 cases in men and 13,630 in women. The report also suggested a likely death toll of around 29,840 (comprising 19,120 males and 10,720 females) due to this disease. Consequently, the rise in liver cancer cases is contributing to the expansion of the primary biliary cholangitis market.
Which Firms Dominate The Primary Biliary Cholangitis Market Segments?
Major companies operating in the primary biliary cholangitis market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck And Co. Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company, Amgen Inc., Boehringer Ingelheim International GmbH., Gilead Sciences Inc., Vertex Pharmaceuticals, Dr. Reddy's Laboratories Ltd., Amneal Pharmaceuticals LLC, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Intercept Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., CureVac N.V., Sangamo Therapeutics Inc., Calliditas Therapeutics AB, NGM Biopharmaceuticals Inc., Bluebird Bio Inc., Intellia Therapeutics Inc., Albireo Pharma Inc., TARGET PharmaSolutions Inc., Genfit S.A., Editas Medicine Inc., CymaBay Therapeutics Inc., Ascletis Pharma Inc.
What Trends Are Expected to Dominate the Primary Biliary Cholangitis Market in the Next 5 Years?
Firms active in the primary biliary cholangitis market are concentrating on improving novel and targeted treatments such as orphan drugs combined with obeticholic acid (OCA) and bezafibrates to treat primary biliary cholangitis (PBC) and achieve market predominance. The aim of combining an orphan drug designation with OCA and bezafibrate is to provide a more complete and efficient method for managing PBC treatment, thus potentially enhancing the life quality of those suffering from this infrequent condition. For instance, Intercept Pharmaceuticals, Inc., a biopharmaceutical company located in the US, got orphan drug designation approval from the FDA in May 2023 for the mixture of obeticholic acid (OCA) and bezafibrate, a PPAR agonist, intended as a possible treatment for primary biliary cholangitis (PBC), a deteriorating liver disease. Also, obeticholic acid (advertised as Ocaliva) is confirmed for PBC treatment in the US.
Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/primary-biliary-cholangitis-global-market-report
Which Is The Largest Region In The Primary Biliary Cholangitis Market?
North America was the largest region in the primary biliary cholangitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary biliary cholangitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Primary Biliary Cholangitis Market?
2. What is the CAGR expected in the Primary Biliary Cholangitis Market?
3. What Are the Key Innovations Transforming the Primary Biliary Cholangitis Industry?
4. Which Region Is Leading the Primary Biliary Cholangitis Market?
Why This Report Matters:
Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.
Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.
Efficient Research: Quickly identify market growth, leading players, and major segments.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Rising Smoking Rates Fueling Growth in the Primary Biliary Cholangitis Market: A Significant Driver Propelling The Primary Biliary Cholangitis Market In 2025 here
News-ID: 4027336 • Views: …
More Releases from The Business Research Company
Comprehensive Insights Into The Global Electric Bikes And Scooters Market: Key G …
The electric bikes and scooters report outlines and analyzes the electric bikes and scooters (excluding e-mopeds or 2-wheelers) market, covering the historic period 2019-2024 and the forecast period 2024-2029 and 2034F. The study examines the market across all regions and major regional economies.
The global electric bikes and scooters (excluding e-mopeds or 2 wheelers) market was valued at approximately $43.09310 billion in 2024, reflecting a CAGR of 12.12% since 2019. The…
Geothermal Heat Pump Market Report 2025: Size, Trends, and Key Growth Insights f …
The geothermal heat pump report outlines and analyzes the geothermal heat pump market, covering 2019-2024 as the historic period and 2024-2029, 2034F as the forecast period. The report examines the market across every region and assesses major economies within each region.
The global geothermal heat pump market reached $4.40620 billion in 2024, increasing at a CAGR of 5.70% since 2019. The market is projected to grow from $4.40620 billion in 2024…
Major Growth Driver Identified in 2025 VFX In Advertising Market: The Rise Of So …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
VFX In Advertising Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
Over the past several years, the market size of vfx in advertising has seen robust growth. It is expected to expand from $2.8 billion in 2024 to a staggering $3.03 billion in 2025, exhibiting…
Driving Web Content, Search Portals And Social Media Market Growth in 2025: The …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Web Content, Search Portals And Social Media Market Size Growth Forecast: What to Expect by 2025?
The market size for web content, search portals, and social media has seen quick expansion in the past few years. It's projected to expand from $682.14 billion in 2024 to $768.29 billion in…
More Releases for Primary
Premier Primary Care Medicine Recognized as Top-Rated Primary Care Physician in …
Premier Primary Care Medicine has been recognized as the top-rated primary care physician in Marietta, Georgia. The designation highlights the practice's commitment to accessible, high-quality primary care, same-day and next-day appointments, and an approach centered on long-term patient relationships.
Marietta, GA - September 16, 2025 - Premier Primary Care Medicine [https://www.premierpcmed.com/] has been recognized as the top-rated primary care physician in Marietta, Georgia. The designation highlights the practice's commitment to accessible,…
Direct Primary Care Market
Direct Primary Care Market Worth 80.4 Bn 2031- Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Direct Primary Care Market"- By Type (Clinical Services, Telehealth Services, Laboratory Services, Consultative Services), Care Setting (Office-Based DPC Practices, Home-Based DPC Practices, Telehealth-Only DPC Practices, Hybrid DPC Practices), End Users (Individuals, Employers, Small Businesses, Large Corporations, Insurance Companies (offering DPC as…
Primary Sclerosing Cholangitis Market
Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease characterized by inflammation and scarring of the bile ducts, leading to liver damage and, ultimately, liver failure. The disease progresses slowly and often goes unnoticed in its early stages. Although the exact cause of PSC remains unknown, it is commonly associated with other inflammatory bowel diseases, particularly ulcerative colitis. The management of PSC includes symptom control, slowing disease progression, and…
Primary Healthcare Conference 2023
3rd World Congress on Primary Healthcare and Medicare Summit
Mercure Roma West, Viale degli Eroi di Cefalonia, 301, 00128 Rome, Italy
Email primaryhealthcare@pulsusgathering.org
On behalf of the Conference Organizing Committee, we would like to invite all of you for the "3rd Word Congress on Primary Healthcare and Medicare", which is going to be held in Rome, Italy on September 21-23, 2023. Primary Healthcare 2023 focuses on the basic theme "To Manifest the Multimorbidity…
Primary Lithium Battery (Primary Lithium Batteries) Market Key Companies and Ana …
The global lithium primary batteries market size will grow from $2.83 billion in 2022 to $2.9 billion in 2023 at a compound annual growth rate (CAGR) of 2.5%
Global " Primary Lithium Battery (Primary Lithium Batteries) Market" 2022 Reports give a Key study on the industry status of the Primary Lithium Battery (Primary Lithium Batteries) Manufacturer with the specific statistics, meaning, definition, SWOT Analysis, expert opinion, and recent development across…
Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include:
1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk…
